Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 6,193 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Ebola Virus Disease
Interventions: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water; Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Decatur, Georgia • St Louis, Missouri

Conditions: Breast Cancer
Interventions: Group 1, Group 2, Group 3; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions: Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Bromide, Fluticasone Propionate/Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 35
States / cities: Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more

Conditions: School Adjustment, Foster Care Disruptions
Interventions: LINKS; Behavioral
Lead sponsor: Oregon Social Learning Center; Other
Eligibility: 9 Years to 13 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: San Diego, California • Eugene, Oregon

Conditions: Obesity, Overweight
Interventions: Choices; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 8 Years to 11 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Hepatitis C
Interventions: DVD Intervention; Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 49 Years
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: General Medical Inpatient Conditions
Interventions: Patient-Centered Transition Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Substance Use
Interventions: Standard Treatment as Usual, CBT4CBT plus Standard treatment as usual; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: New Haven, Connecticut

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Gilbert, Arizona • Upland, California • South Miami, Florida + 10 more

Conditions: Diabetes Type 2
Interventions: Project Dulce + Dulce Digital; Behavioral
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: National City, California • San Diego, California

Conditions: Chronic Disease
Interventions: Transitions of care; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Caregiver Burnout
Interventions: Asthma Academy, Telehealth Visit; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Ovarian Cancer
Interventions: Niraparib; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Jacksonville, Florida • Miami, Florida

Conditions: Rett Syndrome
Interventions: Trofinetide, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 5 Years to 20 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more

Conditions: Glaucoma
Interventions: Test-Brinzolamide 1% Ophthalmic suspension, Reference-Brinzolamide 1% Ophthalmic suspension; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Newport Beach, California • Largo, Florida • Miami, Florida + 7 more

Conditions: Pain, Postoperative
Interventions: OxyCODONE 5 mg Oral Tablet, Acetaminophen 500Mg Tab, Naproxen 500 Mg; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions: Multiprong CDS with referral to pharmacist co-management, Multiprong CDS with GDMT order set, Focused education; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
Interventions: Psilocybin; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Parkinson Disease, Idiopathic Parkinson Disease
Interventions: [F-18] Fluorodopa Positron Emission Tomography, OM Meditation; Drug · Behavioral
Lead sponsor: Andrew Newberg; Other
Eligibility: 25 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more

Conditions: New Daily Persistent Headache (NDPH)
Interventions: Naltrexone HCl (Bulk) Powder; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Early Highly Effective Therapies Group, Escalation Therapies Group; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more

Conditions: Opioid Use Disorder, Opioid Use
Interventions: Sub-acute stabilization; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Immunology of Ebola Vaccine

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Foster Teens' Risk During Transition

CHOICES: Family Physicians Treat Overweight Children

DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice Clients

IMPaCT (Individualized Management Towards Patient-Centered Targets)

CBT for Spanish Speakers

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Project Dulce for Filipino-Americans With Type 2 Diabetes

A Pharmacist-led Transitions of Care Program

Asthma Academy: Use of Simulation and Telehealth to Empower Family Caregivers

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Pain Management After Surgery

Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data